Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

Fig. 4

Prognostic analysis for IGHV ongoing SHM. a Schematic illustration of the putative pathologic origins of IGV SHM and ongoing SHM in DLBCL founder clones and subclones. Transformation can occur in different stages of B-cell development. When DLBCL abnormalities are sufficient to drive lymphomagenesis, DLBCL cells exit the germinal center reaction. Predominant DLBCL clones may exhibit intra-clonal IGV variations conferred by the ongoing SHM process. b IGHV ongoing SHM was associated with significantly poorer overall survival (OS) in the overall study cohort. c IGHV ongoing SHM was associated with poorer OS in the overall validation cohort and in cases without BCL2 rearrangement (BCL2-R) in both the training and validation sets

Back to article page